A study has discovered the first genetic marker that can distinguish between aggressive versus benign bone tumors.
Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature
In this report the authors discuss diagnosis and treatment of a patient with leiomyosarcoma of the stomach, whose disease progressed 2 years after he was disease-free following initial treatment.
A team of scientists have bound gene editing CRISPR/Cas9 to nucleotide aptamers to selectively target and edit osteosarcoma cancer cells.
The largest genomics study of chordoma to date has discovered a gene mutation possessed by some patients which is a target for existing drugs known as PI3K inhibitors. Previously, these drugs have not been considered for chordoma.
Editor, Jade Parker recently spoke with world-renowned sarcoma expert, Robin L Jones. In this interview discover challenges in the diagnosis, treatment and clinical trials of sarcoma and other rare tumors.
A new study suggests that the ribosomal protein P-S6S240 could represent a marker of poor prognosis and a therapeutic target in uterine leiomyosarcoma.
In this special report from Epigenomics, the authors explore the importance of DNA methylation-associated epigenetic changes in chrondrosarcoma.
Study highlights the hedgehog signaling pathway as a potential target for future drug design in gastrointestinal stromal tumors.
A new gene test could identify which patients are likely to suffer more aggressive forms of rhabdomyosarcoma, and thus are in need of more intensive therapy.
Scientists have developed technology to mimic the real-life conditions that facilitate bone tumor growth, showing how the effect of an anticancer drug changes according to the forces experienced by the cells.